TOP TEN perturbations for 39112_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39112_at
Selected probe(set): 202152_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39112_at (202152_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):-1.5070267Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
| Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 cell sample |
| Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):-1.479764Number of Samples:2 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
renal cell carcinoma study 6 (chromophobe type) / normal kidney tissue (fetal)
Relative Expression (log2-ratio):1.4310341Number of Samples:4 / 2
| Experimental | renal cell carcinoma study 6 (chromophobe type) |
| Tumor tissue samples from the kidney of patients with chromophobe renal cell carcinoma (cRCC). | |
| Control | normal kidney tissue (fetal) |
| Normal fetal kidney tissue samples. |
small cell lung cancer study 4 (XCL from CDX) / small cell lung cancer study 4 (cell line)
Relative Expression (log2-ratio):-1.3586044Number of Samples:11 / 4
| Experimental | small cell lung cancer study 4 (XCL from CDX) |
| Xenograft-derived cell lines (XCL) established from a small cell lung carcinoma (SCLC) publicly available cell lines derived xenografts (CDX derived cell lines). Xenografts were grown in the flanks of a nude mice. Obtained cells were cultivated under conventional tissue culture conditions. | |
| Control | small cell lung cancer study 4 (cell line) |
| Various small cell lung cancer (SCLC) publicly available cell lines samples. |
brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):-1.2243538Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 DICER1(-/-) cell sample |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (10000 uM; Hep-G2) / vehicle (PBS) treated Hep-G2 cell sample
Relative Expression (log2-ratio):1.216362Number of Samples:3 / 6
| Experimental | 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (10000 uM; Hep-G2) |
| Hep-G2 cells exposed to 10000 uM 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (dissolved in PBS) for 72 hours. Cells were exposed to the chemical when 80% confluence was reached. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:--- | |
| Control | vehicle (PBS) treated Hep-G2 cell sample |
| Hep-G2 cells treated with vehicle (PBS) for 72 hours. Cells were exposed to the vehicle when 80% confluence was reached. |
endometriosis study 6 (minimal/mild endo.; pro. MCP) / normal endometrium tissue (pro. MCP)
Relative Expression (log2-ratio):1.2147245Number of Samples:12 / 20
| Experimental | endometriosis study 6 (minimal/mild endo.; pro. MCP) |
| Endometrial tissue samples from women with minimal or mild endometriosis and pelvic pain and/or infertility collected in the proliferative menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | normal endometrium tissue (pro. MCP) |
| Normal endometrial tissue samples from women collected in the proliferative menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. |
T-cell isolation study 11 / T-cell isolation study 6
Relative Expression (log2-ratio):1.168169Number of Samples:2 / 2
| Experimental | T-cell isolation study 11 |
| CD4+ resting memory T-cell were isolated from peripheral blood buffy coat of healthy donors after storage for 24 hours at 20°C. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population. | |
| Control | T-cell isolation study 6 |
| CD4+ resting memory T-cell were isolated from whole peripheral blood of healthy donors with no delay. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population. |
precursor-B-ALL study 7 (PDX; long-term; >10wk) / precursor-B-ALL study 7 (late relapse; >24m)
Relative Expression (log2-ratio):-1.1563339Number of Samples:7 / 8
| Experimental | precursor-B-ALL study 7 (PDX; long-term; >10wk) |
| Leukemia cell samples isolated from spleen of patient derived xenografts (PDX) of precursor B-cell acute lymphoblastic leukemia generated in NOD/SCID mice with time to manifestation of leukemia (TTL) more than 10 weeks (long-term). Cell suspensions containing more than 90% leukemia cells as estimated by flow cytometry were prepared from infiltrated spleens of leukemia bearing mice. Briefly, unconditioned NOD/SCID (NOD.CB17-Prkdcscid/NCrCrl) mice with a median age of 10 weeks were transplanted by injection of patient leukemia cells, which were isolated from bone marrow or peripheral blood of pediatric patients with precursor BCP-ALL, into the lateral tail vein. Upon clear evidence for leukemia related morbidity, mice were killed and autopsy was performed. Leukemia was confirmed detecting leukemia cells in bone marrow, spleen and peripheral blood. Time to leukemia (TTL) was determined as weeks from transplant to clinical leukemia manifestation. Donor characteristics: 3 females and 9 males; 1-9 years old; good response to prednison; no fusion gene; remision at day 33; non-high risk group; late relapse group (relapse after 24 months from diagnosis). | |
| Control | precursor-B-ALL study 7 (late relapse; >24m) |
| Leukemia cell samples isolated from bone marrow of pediatric patients with precursor B-cell acute lymphoblastic leukemia (B-ALL) with relapse after 24 months from diagnosis (late relapse). White blood cells were isolated through Ficoll-Hypaque density gradient centrifugation. All diagnostic leukemia samples were obtained before treatment from pediatric de novo B cell precursor ALL patients (BCP-ALL). Samples obtained from studies registred under NCT00430118 and NCT00613457. |
galectin-1 study 1 / vehicle (DTT/polym. B) treated monocyte sample
Relative Expression (log2-ratio):-1.1557436Number of Samples:3 / 3
| Experimental | galectin-1 study 1 |
| Monocytes were plated in 12-well plates and differentiated in RPMI 1640 containing 10% FBS plus 50 ng/ml (>500 U/ml) GM-CSF and 100 ng/ml (>500 U/ml) IL-4 for 5 days. At day 5, galectin-1 (20 μM) in the presence of 10 μg/ml polymyxin B was added. At 18 h after treatment, total RNA was isolated. | |
| Control | vehicle (DTT/polym. B) treated monocyte sample |
| Monocytes were plated in 12-well plates and differentiated in RPMI 1640 containing 10% FBS plus 50 ng/ml (>500 U/ml) GM-CSF and 100 ng/ml (>500 U/ml) IL-4 for 5 days. At day 5, vehicle consisting of equivalent volume of 8 mM DTT (galectin-1 storage buffer) and 10 μg/ml polymyxin B was added. At 18 h after treatment, total RNA was isolated. |